Tickerlog
NASDAQ
$27.06
-28.747
-1.046
Updated Friday 8th of April 2022 08:18:24 AM

ACADIA Pharmaceuticals Inc. Common Stock

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
EBITDA $
ROE -28.747
EPS -1.046
Marketcap$4.4B
Free Cash Flow$
Health Care
Biotechnology: Pharmaceutical Preparations

Top gainers today
Top losers today